VANCOUVER, B.C., December 9, 2011 – CRH Medical Corporation (TSX-V: CRM, OTCQX: CRMMF), a North American medical company focused on providing physicians with innovative products for the treatment of gastrointestinal diseases, today announced that its Board of Directors, as part of its year end compensation process, has authorized the grant of an aggregate of 950,000 incentive stock options (the “Options”) to senior executives and directors of CRH, at an exercise price of $0.56 per share. The Options are exercisable for a five-year period from the date of grant and will vest 1/16th every three months for four years. CRH’s Stock Option Plan has been approved by its shareholders and the TSX Venture Exchange.
About CRH Medical Corporation:
CRH Medical Corporation specializes in the distribution of innovative medical products directly to physicians, particularly those in the gastroenterologist community. The Company’s CRH O’Regan System, is a single use, disposable, hemorrhoid treatment that is safe and highly effective in treating hemorrhoid grades I – IV. The O’Regan System is rapidly emerging as the standard of care with gastroenterologists who treat hemorrhoids. In addition to the product, CRH Medical delivers clinical, marketing and operational support directly to its partner physicians. CRH utilizes its web-based platform to connect doctors with patients as well as educating its ever increasing install base of physicians.
For further information, please contact
Adam Peeler, Media and Investor Relations
416.815.0700 x 225
Additional information may also be found by visiting the Company’s website at www.crhmedcorp.com or the SEDAR website at www.sedar.com. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.